Home Newsfeeds EF Hutton Maintains Buy on Hoth Therapeutics, Lowers Price Target to $33

EF Hutton Maintains Buy on Hoth Therapeutics, Lowers Price Target to $33

EF Hutton analyst Constantine Davides maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and lowers the price target from $45 to $33.

byBenzinga Newsdesk

December 30, 2022

1 minute read

EF Hutton analyst Constantine Davides maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and lowers the price target from $45 to $33.

News

HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024

By Benzinga Newsdesk

April 5, 5:18 AM

Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other menin

HCM

News

Halliburton CEO Says ‘Almost Impossible’ To Add Frack Capacity In ’22; Says Sees Further Service Price Hikes On Tight Capacity

By Benzinga Newsdesk

July 19, 9:26 AM

-Bloomberg

HAL

Why Imperial Petroleum (IMPP) Stock Is Volatile Today

By Henry Khederian

September 7, 12:35 PM

Imperial Petroleum Inc (NASDAQ: IMPP) shares are trading flat at $1.36, pulling back following earlier strength, after the company disclosed a $10 million share buyback program and a deal to acquire two vessels.

IMPP